Concord Medical Services Holdings Ltd (CCM) is a leading specialist hospital management group providing integrated services across the entire medical industry value chain in China. Operational since 2007, CCM aims to make high-quality medical services accessible to the Chinese population, positioning itself as one of the largest providers of radiotherapy and diagnostic imaging services in the country.
CCM operates a comprehensive network of medical service centers, working in tandem with more than 200 hospitals across the People's Republic of China, Beijing, Shanghai, Guangzhou, and many others. The company is equipped with top-tier essential medical equipment used in radiotherapy, diagnostic imaging, and various clinical specialties, ensuring they are capable of treating a wide array of medical conditions.
One of CCM’S key offerings is its radiotherapy services, which involves the use of radiation to treat cancer. CCM boasts one of the most extensive radiotherapy networks in China with advanced radiation equipment, significantly contributing to the fight against cancer.
Aside from its impressive network, the company also intelligently integrates technology into its operations, employing a cloud-based system to connect doctors and patients while enabling data sharing and centralized management. This innovative approach significantly enhances the care delivery process, ensuring patients have convenient access to the high quality care they need.
Investors have recognized the potential of CCM’s operative model, despite the uncertainties in the global financial markets, which reflects their confidence in the company's long-term growth trajectory. The company has been listed on the New York Stock Exchange since 2009, demonstrating the credibility and reliability of its operations.
Furthermore, CCM is committed to driving positive social impact. The company is significantly involved in training and development for medical professionals that ultimately contribute to elevating the standard of the care provision in the country.
As of 2021, Concord Medical Services Holdings Ltd embarked upon a diversification strategy which included the establishment of the Concord Cancer Hospital, a 400-bed tertiary hospital in Beijing, thereby underscoring its commitment to providing the best cancer treatment modalities available.
Through the multi-faceted strategy that combines top-notch services, technological innovation, professional development, and a drive to combat cancer, CCM remains a significant player in China's healthcare landscape. The company actively aims to reshape the healthcare experience for patients and healthcare professionals, thereby contributing to the overall development of China's health sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes the one-week stock performance of Petrobras (PBR), Coca-Cola Femsa (KOF), Concord Medical Services (CCM), BP (BP), and Suncor Energy (SU), noting that their recent gains are primarily due to sector momentum rather than company-specific announcements. Concord Medical Services showed the highest weekly gain at 16.56%, while Petrobras had the strongest single-day move on October 14. The author advises investors to verify filings and exercise caution, as sector-driven rallies can quickly reverse.
This article details the top gaining and losing healthcare stocks during Friday's intraday trading session. Quantum-Si and Nautilus Biotechnology led the gainers with significant price increases, while China SXT Pharmaceuticals and SCWorx experienced the largest declines. The report provides stock symbols, percentage changes, and market capitalization for each listed company.
Concord Healthcare Group is experiencing robust growth in its hospital and proton therapy businesses, driven by China's policy to encourage specialized private hospitals and expand commercial health insurance. The company's hospital revenue rose 37.4 percent year-on-year in 2025, reaching 373.26 million yuan and reversing a gross loss from the previous year. Concord is differentiating itself through proton therapy and expanding its payment networks to include commercial and supplementary insurance, while also seeking overseas expansion opportunities.